Tag Archive for: Gilead

A Delaware jury ruled in favor of Gilead Sciences, finding that the company’s HIV prevention medicines Truvada and Descovy do not infringe on U.S. government patents and that the patents themselves are invalid in the first place. The company also announced it was acquiring private San Diego biotech XinThera.

Gilead Sciences is headed to trial in Delaware federal court this week to fight claims that it owes the U.S. government a share of multibillion-dollar profits from its HIV-prevention drug regimen.

Gilead Sciences Inc. on Tuesday unveiled data from the first human study of its experimental oral COVID-19 antiviral, saying the results in healthy volunteers cleared the way for two large Phase III trials of the drug that have begun enrolling patients.

Gilead Sciences Inc. said on Friday the U.S. Food and Drug Administration had greenlighted expanded use of Trodelvy to treat the most common type of breast cancer, marking the third approval for the drug.

Kite’s Christi Shaw, AbbVie’s Jag Dosanjh, and LexisNexis Risk Solution’s Liz Paulson earn top industry honors.

Gilead receives the rights to exclusively license EVOQ’s NanoDisc Technology to develop and commercialize immunotherapy products for rheumatoid arthritis and lupus.

Gilead Sciences will buy all the remaining rights for an experimental cancer therapy, GS-1811, from Jounce Therapeutics for $67 million, the drugmaker said on Tuesday.

The European Union’s health regulator has advised the use of antiviral treatments over monoclonal antibodies to treat COVID-19 in patients at risk of their condition worsening, citing concerns over decreasing effectiveness against newer virus variants.

Sobi North America, a unit of Swedish Orphan Biovitrum AB , said on Thursday the U.S. Food and Drug Administration authorized its arthritis drug for treatment of high-risk hospitalized COVID-19 patients.

Gilead’s hopes for an approval in hepatitis delta virus (HDV) infection and compensated liver disease will have to wait following an FDA rejection.